Sunitinib Malate in Treating Patients With Uterine Cervical Cancer That is Stage IVB, Recurrent, or Cannot Be Removed By Surgery

Inclusion Criteria: * Patients must have histologically or cytologically confirmed squamous cell carcinoma or adenosquamous carcinoma of the cervix; patients with adenocarcinoma of the cervix will also be included since, although infrequent, their management in general is similar to those with squamous tumors * Patients must have advanced (stage IVB) recurrent or persistent disease unsuitable for curative treatment by surgery and/or radiation therapy * Presence of clinically and/or radiologically documented disease; at least one site of disease must be unidimensionally measurable as follows: * X-ray, physical exam \>= 20 mm * Spiral computed tomography (CT) scan \>= 10 mm * Non-spiral CT scan \>= 20 mm * All radiology studies must be performed within 21 days prior to registration (within 28 days if negative) * Patients must have a life expectancy of at least 12 weeks * Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1; performance status (PS) 2 patients are eligible if, in the opinion of the investigator, they are suitable for inclusion in the study and are likely to be compliant with the study procedures (in particular the recommendations for supportive care and dose modifications) * Patients may have had neoadjuvant or adjuvant chemotherapy * Patients may have had concurrent chemoradiation; this is not considered neoadjuvant or adjuvant treatment * Patients may have had no more than one prior chemotherapy regimen for recurrent metastatic disease;…